Synopsis
Synopsis
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
Europe
0
Canada
0
Australia
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Docatone
2. Dopram
3. Doxapram
4. Hydrochloride, Doxapram
1. 113-07-5
2. Stimulexin
3. Dopram
4. 1-ethyl-4-(2-morpholinoethyl)-3,3-diphenylpyrrolidin-2-one Monohydrochloride
5. Doxapram Hydrochloride Anhydrous
6. Doxapram (hydrochloride)
7. Fb8713u6dm
8. 1-ethyl-4-(2-morpholin-4-ylethyl)-3,3-diphenylpyrrolidin-2-one;hydrochloride
9. 1-ethyl-4-(2-morpholinoethyl)-3,3-diphenylpyrrolidin-2-onemonohydrochloride
10. Dsstox_cid_27815
11. Dsstox_rid_82579
12. Dsstox_gsid_47837
13. Doxapramhydrochloride
14. Chebi:59837
15. Ahr-619
16. Cas-113-07-5
17. 3,3-diphenyl-1-ethyl-4-(2-morpholinoethyl)-2-pyrrolidinone Hydrochloride
18. 1-ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-2-pyrrolidinone Hydrochloride Hydrate
19. 2-pyrrolidinone, 1-ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-, Monohydrochloride, Monohydrate
20. Ncgc00167459-01
21. Unii-fb8713u6dm
22. Einecs 204-022-3
23. 2-pyrrolidinone, 1-ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-, Monohydrochloride
24. Schembl40645
25. Mls001424142
26. Chembl1200876
27. Dtxsid9047837
28. Tox21_112463
29. Mfcd00072148
30. Nsc170958
31. Akos015906444
32. Tox21_112463_1
33. Ac-4694
34. Ccg-101076
35. Ccg-221205
36. Nc00326
37. Nsc 170958
38. Sb18933
39. 2-pyrrolidinone, 1-ethyl-4-(2-(4-morpholinyl)ethyl)-3,3-diphenyl-, Monohydrochloride
40. Ncgc00167459-02
41. As-13336
42. Smr000469229
43. 2-pyrrolidinone,3-diphenyl-, Monohydrochloride
44. 081d530
45. 113d075
46. J-002892
47. Q27126918
48. 1-ethyl-4-(2-morpholinoethyl)-3,3-diphenylpyrrolidin-2-one Hydrochloride
49. (+/-)-1-ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-2-pyrrolidinone Monohydrochloride
50. 2-pyrrolidinone, 1-ethyl-4-(2-(4-morpholinyl)ethyl)-3,3-diphenyl-, Hydrochloride, Hydrate (1:1:1)
51. 2-pyrrolidinone, 1-ethyl-4-(2-(4-morpholinyl)ethyl)-3,3-diphenyl-, Monohydrochloride, (+/-)-
Molecular Weight | 415.0 g/mol |
---|---|
Molecular Formula | C24H31ClN2O2 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 3 |
Rotatable Bond Count | 6 |
Exact Mass | 414.2074059 g/mol |
Monoisotopic Mass | 414.2074059 g/mol |
Topological Polar Surface Area | 32.8 Ų |
Heavy Atom Count | 29 |
Formal Charge | 0 |
Complexity | 487 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 1 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 2 | |
---|---|
Drug Name | Doxapram hydrochloride |
Drug Label | DOPRAM Injection (doxapram hydrochloride injection, USP) is a clear, colorless, sterile, non-pyrogenic, aqueous solution with pH 3.5 to 5, for intravenous administration.Each 1 mL contains:Doxapram Hydrochloride, USP .................................... |
Active Ingredient | Doxapram hydrochloride |
Dosage Form | Injectable |
Route | Injection |
Strength | 20mg/ml |
Market Status | Prescription |
Company | Bedford |
2 of 2 | |
---|---|
Drug Name | Doxapram hydrochloride |
Drug Label | DOPRAM Injection (doxapram hydrochloride injection, USP) is a clear, colorless, sterile, non-pyrogenic, aqueous solution with pH 3.5 to 5, for intravenous administration.Each 1 mL contains:Doxapram Hydrochloride, USP .................................... |
Active Ingredient | Doxapram hydrochloride |
Dosage Form | Injectable |
Route | Injection |
Strength | 20mg/ml |
Market Status | Prescription |
Company | Bedford |
Central Nervous System Stimulants
A loosely defined group of drugs that tend to increase behavioral alertness, agitation, or excitation. They work by a variety of mechanisms, but usually not by direct excitation of neurons. The many drugs that have such actions as side effects to their main therapeutic use are not included here. (See all compounds classified as Central Nervous System Stimulants.)
Respiratory System Agents
Drugs used for their effects on the respiratory system. (See all compounds classified as Respiratory System Agents.)
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Related Excipient Companies
Excipients by Applications
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
34
PharmaCompass offers a list of Doxapram Hydrochloride API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Doxapram Hydrochloride manufacturer or Doxapram Hydrochloride supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Doxapram Hydrochloride manufacturer or Doxapram Hydrochloride supplier.
PharmaCompass also assists you with knowing the Doxapram Hydrochloride API Price utilized in the formulation of products. Doxapram Hydrochloride API Price is not always fixed or binding as the Doxapram Hydrochloride Price is obtained through a variety of data sources. The Doxapram Hydrochloride Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A (+-)-1-Ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-2-pyrrolidinone monohydrochloride monohydrate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of (+-)-1-Ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-2-pyrrolidinone monohydrochloride monohydrate, including repackagers and relabelers. The FDA regulates (+-)-1-Ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-2-pyrrolidinone monohydrochloride monohydrate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. (+-)-1-Ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-2-pyrrolidinone monohydrochloride monohydrate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of (+-)-1-Ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-2-pyrrolidinone monohydrochloride monohydrate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A (+-)-1-Ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-2-pyrrolidinone monohydrochloride monohydrate supplier is an individual or a company that provides (+-)-1-Ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-2-pyrrolidinone monohydrochloride monohydrate active pharmaceutical ingredient (API) or (+-)-1-Ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-2-pyrrolidinone monohydrochloride monohydrate finished formulations upon request. The (+-)-1-Ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-2-pyrrolidinone monohydrochloride monohydrate suppliers may include (+-)-1-Ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-2-pyrrolidinone monohydrochloride monohydrate API manufacturers, exporters, distributors and traders.
click here to find a list of (+-)-1-Ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-2-pyrrolidinone monohydrochloride monohydrate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A (+-)-1-Ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-2-pyrrolidinone monohydrochloride monohydrate DMF (Drug Master File) is a document detailing the whole manufacturing process of (+-)-1-Ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-2-pyrrolidinone monohydrochloride monohydrate active pharmaceutical ingredient (API) in detail. Different forms of (+-)-1-Ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-2-pyrrolidinone monohydrochloride monohydrate DMFs exist exist since differing nations have different regulations, such as (+-)-1-Ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-2-pyrrolidinone monohydrochloride monohydrate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A (+-)-1-Ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-2-pyrrolidinone monohydrochloride monohydrate DMF submitted to regulatory agencies in the US is known as a USDMF. (+-)-1-Ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-2-pyrrolidinone monohydrochloride monohydrate USDMF includes data on (+-)-1-Ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-2-pyrrolidinone monohydrochloride monohydrate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The (+-)-1-Ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-2-pyrrolidinone monohydrochloride monohydrate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of (+-)-1-Ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-2-pyrrolidinone monohydrochloride monohydrate suppliers with USDMF on PharmaCompass.
A (+-)-1-Ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-2-pyrrolidinone monohydrochloride monohydrate CEP of the European Pharmacopoeia monograph is often referred to as a (+-)-1-Ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-2-pyrrolidinone monohydrochloride monohydrate Certificate of Suitability (COS). The purpose of a (+-)-1-Ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-2-pyrrolidinone monohydrochloride monohydrate CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of (+-)-1-Ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-2-pyrrolidinone monohydrochloride monohydrate EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of (+-)-1-Ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-2-pyrrolidinone monohydrochloride monohydrate to their clients by showing that a (+-)-1-Ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-2-pyrrolidinone monohydrochloride monohydrate CEP has been issued for it. The manufacturer submits a (+-)-1-Ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-2-pyrrolidinone monohydrochloride monohydrate CEP (COS) as part of the market authorization procedure, and it takes on the role of a (+-)-1-Ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-2-pyrrolidinone monohydrochloride monohydrate CEP holder for the record. Additionally, the data presented in the (+-)-1-Ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-2-pyrrolidinone monohydrochloride monohydrate CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the (+-)-1-Ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-2-pyrrolidinone monohydrochloride monohydrate DMF.
A (+-)-1-Ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-2-pyrrolidinone monohydrochloride monohydrate CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. (+-)-1-Ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-2-pyrrolidinone monohydrochloride monohydrate CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of (+-)-1-Ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-2-pyrrolidinone monohydrochloride monohydrate suppliers with CEP (COS) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing (+-)-1-Ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-2-pyrrolidinone monohydrochloride monohydrate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for (+-)-1-Ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-2-pyrrolidinone monohydrochloride monohydrate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture (+-)-1-Ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-2-pyrrolidinone monohydrochloride monohydrate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain (+-)-1-Ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-2-pyrrolidinone monohydrochloride monohydrate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a (+-)-1-Ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-2-pyrrolidinone monohydrochloride monohydrate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of (+-)-1-Ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-2-pyrrolidinone monohydrochloride monohydrate suppliers with NDC on PharmaCompass.
(+-)-1-Ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-2-pyrrolidinone monohydrochloride monohydrate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of (+-)-1-Ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-2-pyrrolidinone monohydrochloride monohydrate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right (+-)-1-Ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-2-pyrrolidinone monohydrochloride monohydrate GMP manufacturer or (+-)-1-Ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-2-pyrrolidinone monohydrochloride monohydrate GMP API supplier for your needs.
A (+-)-1-Ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-2-pyrrolidinone monohydrochloride monohydrate CoA (Certificate of Analysis) is a formal document that attests to (+-)-1-Ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-2-pyrrolidinone monohydrochloride monohydrate's compliance with (+-)-1-Ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-2-pyrrolidinone monohydrochloride monohydrate specifications and serves as a tool for batch-level quality control.
(+-)-1-Ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-2-pyrrolidinone monohydrochloride monohydrate CoA mostly includes findings from lab analyses of a specific batch. For each (+-)-1-Ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-2-pyrrolidinone monohydrochloride monohydrate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
(+-)-1-Ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-2-pyrrolidinone monohydrochloride monohydrate may be tested according to a variety of international standards, such as European Pharmacopoeia ((+-)-1-Ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-2-pyrrolidinone monohydrochloride monohydrate EP), (+-)-1-Ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-2-pyrrolidinone monohydrochloride monohydrate JP (Japanese Pharmacopeia) and the US Pharmacopoeia ((+-)-1-Ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-2-pyrrolidinone monohydrochloride monohydrate USP).